HLAVNÍ TÉMA Katecholamínmi indukované kardiomyopatie u pacientov s feochromocytómom | 21 / Vnitř Lék. 2024;70(1):17-21 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz ných niekoľko kazuistík, ktoré dokumentujú prípady pacientov, kde sa po transplantácii srdca pre terminálne srdcové zlyhávanie zistila prítomnosť PPGL (25, 41). Na skríning PPGL by sa malo myslieť u pacientov so srdcovým zlyhávaním, najmä ak ide o mladší vek pacienta, rezistentnú artériovú hypertenziu, paroxyzmálnu hypertenziu sprevádzanú vegetatívnou symptomatológiou. Vyšetrenie metanefrínov by malo byť však optimálne realizované až po kompenzácii a odznení akútnej fázy, pre možnú falošnú pozitivitu pri akútnych stresových stavoch (15, 25). Záver CICMP predstavujú zriedkavú, avšak veľmi závažnú až potenciálne fatálnu komplikáciu PPGL. Včasná diagnostika a adekvátny manažment vedie u väčšiny pacientov k zlepšeniu až normalizácii funkcie srdca. V prípade neliečených pacientov, resp. pacientov s inoperabilnými alebo metastatickými formami PPGL, je miera mortality vysoká, presahuje 30 %. U cca 5 % pacientov môže byť srdcové zlyhávanie prvým prejavom PPGL, preto je potrebné zvažovať PPGL v diferenciálnej diagnostike príčin niektorých druhov kardiomyopatií (25). PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Ne. Poděkování: N/A. Registrace v databázích: N/A. Projednání etickou komisí: N/A. LITERATÚRA 1. Pacak K. New biology of pheochromocytoma and paraganglioma. Endocrine Practice. 2022;28:1253-1269. 2. Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocrine Regulations 2019; 53(3):191-212. 3. Fishbein L, et al. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment. Hematol Oncol Clin North Am. 2016; 30(1):135-50. 4. Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma-Pheochromocytoma Syndromes. 2008 May 21 [Updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1548/ 5. Eisenhofer G, Lenders JWM. Biochemical diagnosis of pheochromocytoma, a rediscovered catecholamine-metabolizing tumor. Clin Chem. 2018;64(12):1780-1781. 6. Kumar A, Pappachan JM, Fernandez CJ. Catecholamine-induced cardiomyopathy: an endocrinologist‘s perspective. Rev Cardiovasc Med. 2021;22(4):1215-1228. 7. Van Vliet PD, Burchell HB, Titus JL. Focal Myocarditis Associated With Pheochromocytoma. N Engl J Med. 1966; 274(20):1102-8. 8. Ferreira VM, Marcelino M, Piechnik SK, et al. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. J Am Coll Cardiol. 2016; 67(20):2364-2374. 9. Wu Y, Zeng L, Zhao S, et al. Ligands of Adrenergic Receptors: A Structural Point of ViewBiomolecules. 2021;11(7):936. 10. Brodde OE et Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51(4):651-690. 11. Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha -2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31-9. 12. Steinberg SF. Beta1-adrenergic receptor regulation revisited; the role of the extracellular N-terminus. Circ Res. 2018;123(11):1199-1201. 13. Dubois-Deruy E, Gelinas R, Beauloye C, et al. Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP-activated protein kinase and autophagy ESC Heart Fail. 2020;7(3):920-932. 14. Eisenhofer G, Pacak K, Huynh T-T, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2010;18:97-111. 15. Santos JR, Broffferio A, Viana B, et al. catecholamine-induced cardiomyopathy in pheochromocytoma: How to manage a rare complication in a rare disease? Horm Metab Res. 2019;51(7):458-469. 16. Haft JI, Fani K. Stress and the induction of intravascular platelet aggregation in the heart. Circulation. 1973;48:164-169. 17. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine Metabolism: a Contemporary View with Implications for Phsyiology and Medicine. Pharmacological Reviews. 2004;56:331-349. 18. Dhalla NS. Formation of Aminochrome Leads to Cardiac Dysfunction and Sudded Cardiac Death. Circulation Research. 2018;123:409-411. 19. Tsujimoto G, Manager WM, Hoffman BB. Desensitization of beta-adrenergic receptors by pheochromocytoma. Endocrinology. 1984;114:1272-1278. 20. Golbasi Z, Sakalli M, Cicek D, et al. dynamic left ventricular outflow tract obstruction in a patient with pheochromocytoma. Jpn Heart J. 1999;40:831-835. 21. Agrawal S, Shirabi J, Garg L, et al, Pheochromocytoma and stress cardiomyopathy: insight into pathogenesis. World Journal of Cardiology. 2017;9:255-260. 22. Batisse-Lignier M, Pereira B, Motreff P, et al. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses? A Systematic Analytical Review. Medicine 2015;94:50. 23. Ferreira VM, Marcelino M, Piechnik SK et al. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. J Am Coll Cardiol. 2016;67(20):2364-2374. 24. Agarwal V, Kant G, Hand N, et al. Takotsubo-like cardiomyopathy in pheochromocytoma. International Journal of Cardiology. 2011;153(3):241-248. 25. Szatko A, Glinicki P, Gietka-Czernel M. Pheochromocytoma/paraganglioma-associaated cardiomyopathy. Froniters in Endocrinology. 2023. doi 10.3389/fendo.2023.1204851. 26. Y-Hassan S, Falhammar H. Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered takotsubo syndrome: a systemiatic review and meta-analysis of 156 published cases. Clin cardiol. 2020;43(5):459-467. 27. Cornu E, Motiejunaite J, Belmihoub I, et al. Acute Stress Cardiomyopathy: Heart of pheochromocytoma. Ann Endocrinol (Paris) 2021;82(3-4):201-205. 28. Gagnon N, Mansour S, Bitton Y, et al. Takotsubo-like cardiomyopathy in a Large cohort of patients with pheochromocytoma and paraganglioma. Endocr Pract. 2017;23(10):1178-92. 29.Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. 30. Prys-Roberts C, Farndon JR. Efficiacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002;26(8):1037-42. 31. Buitenwerf E, Osinga TE, Timmers H, et al. Efficiacy of alpha-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial. J Clin Endocrinol Metab. 2020;105(7):2381-91. 32. Mateucci M, Kowalewski M, Fina D et al. Extracorporeal life support for pheochromocytoma-induced cardiogenic shock: a systematic review. Perfusion. 2020;35 (1_suppl):20-28. 33. Choudhary M, Chen Y, Friedman O, et al. Pheochromocytoma Crisis Presenting With ARDS Successfully Treated With ECMO-Assisted Adrenalectomy. AACE Clin Case Rep. 2021;7(5):310-314. 34. Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature, Int J Cardiol. 2017;249:319-23. 35. Wani A, Adil A, Gardezi SAA et al. Pheochromocytoma presenting as hypertrophic obstructive cardiomyopathy. JAMA cardiol. 2021;6(8):974-6. 36. Huddle KR, Kalliatkis B, Skoularigis J. Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. Ches.t 1996;109(5):1394-7. 37. Jacob JL, da Silveira LC, de Freitas CG, et al. Pheochromocytoma with echocardiographic features of obstructive cardiomyopathy a case report. Angiology. 1994;45(11):985-9. 38. Wang Y, Yu X, Huang Y. Predictive factors for catecholamine- induced cardiomyopathy in patients with pheochromocytoma and paraganglioma. Front Endocrinol. (Lausanne) 2022;13:853878. 39. Amar J, Brunel J, Cardot Bauters C, et al. Genetic biomarkers of life-threatening pheochromocytoma-induced cardiomyopathy Endocr Relat Cancer. 2022;29(5):267-272. 40. Zhou J, Xuan H, Miao Y et al. Acute cardiac complications and subclinical myocardial injuries associated with pheochromocytoma and paraganglioma. BMC Cardiovasc Disord. 2021;21:203. 41. Dalby MC, Burke M, Radley-Smith R, et al. Pheochromocytoma presenting after cardiac transplantation for dilated cardiomyopathy. J Heart Lung Transplant. 2001;20(7):773-5.
RkJQdWJsaXNoZXIy NDA4Mjc=